NCT06702098 2024-11-22
iNK-r/r AML
Guangzhou Ruixin Biotechnological Co., LTD
Phase EARLY_PHASE1 Not yet recruiting
Clinical Trials
7 trialsNCT06541405 2024-08-07
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT06541444 2024-08-07
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT03224819 2023-09-01
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Amgen
Phase EARLY_PHASE1 Terminated
NCT05722171 2023-02-10
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05432401 2022-06-27
TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04209712 2020-07-29
Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Phase EARLY_PHASE1 Unknown